Core Viewpoint - A class action lawsuit has been filed against Tempus AI, Inc. for alleged violations of securities laws, specifically related to misleading statements made by the company during the class period from August 6, 2024, to May 27, 2025 [1][2][4] Group 1: Lawsuit Details - The Schall Law Firm is representing investors in a class action lawsuit against Tempus AI, Inc. for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1] - Investors who purchased Tempus securities during the specified class period are encouraged to contact the law firm before August 12, 2025, to participate in the lawsuit [2] - The class has not yet been certified, meaning that potential class members are not yet represented by an attorney [3] Group 2: Allegations Against Tempus - The complaint alleges that Tempus made false and misleading statements regarding the value of various contracts, including those with related parties and self-funded agreements [4] - Concerns were raised about Tempus's joint venture with SoftBank, which was at risk of being discredited due to the appearance of "round-tripping" capital to inflate revenue [4] - The acquisition of Ambry by Tempus is highlighted as problematic due to its aggressive and potentially unethical business practices, contributing to the misleading nature of the company's public statements [4]

Core Viewpoint - Tempus AI's stock price fell over 5% following the announcement of a $400 million convertible preferred note issuance, reflecting investor concerns about potential equity dilution [1][2] Financing Plan - Tempus AI plans to issue $400 million in convertible preferred notes, maturing on July 15, 2030, with semi-annual interest payments [1] - The specific interest rate and initial conversion price will be determined during the final pricing phase [1] - The company grants underwriters a 13-day over-allotment option to purchase up to an additional $60 million in notes [1] Use of Proceeds - The net proceeds from the issuance will primarily be used for three purposes: 1. To fully repay existing secured term loan principal and interest of $274.7 million 2. To cover costs related to capped call option transactions 3. To support the company's general operating funds [1] Strategic Intent - The financing plan indicates the company's strategy to optimize its capital structure, utilizing convertible debt to secure medium to long-term funding while allowing investors the potential for equity upside [1] - The concurrent debt refinancing operation aims to reduce existing debt costs and enhance financial health [1]

Core Viewpoint - The healthcare sector is highlighted as a critical area in the stock market, driven by the need for innovative therapies and medical technologies to address an aging population and rising chronic diseases. There are ten under-the-radar healthcare stocks identified as potential investment opportunities. Group 1: Company Highlights - **Certara**: Positioned to benefit from AI-driven transformations in medicine, providing bio-simulation software that accelerates drug development, with over 90% of novel drugs approved by the FDA since 2014 utilizing its technology [3][4]. - **Beam Therapeutics**: A clinical-stage biotech focusing on precision gene editing therapies for genetic diseases, with its lead candidate in phase 1/2 trials for sickle cell disease, showing promise for long-term growth [5][6]. - **Inspire Medical Systems**: Develops implantable devices for obstructive sleep apnea, reporting a 23% year-over-year revenue increase to $201 million, indicating strong market demand [8]. - **Insulet**: Specializes in tubeless insulin pump technology, targeting a revenue growth of 19% to 22% by 2025, with significant expansion opportunities in international markets [9]. - **Krystal Biotech**: Focuses on rare skin diseases, with its gene therapy expected to generate approximately $400 million in revenue this year, reinforcing its market position [10]. - **LifeMD**: Operates a telehealth platform with a 49% year-over-year revenue increase, driven by a partnership with Novo Nordisk, indicating potential for further growth [11]. - **Option Care Health**: Leading provider of home infusion services, positioned to benefit from the shift towards personalized healthcare [12]. - **Tempus AI**: Utilizes AI for precision medicine, projecting over 80% revenue growth this year to about $1.3 billion, highlighting its expansive data ecosystem [13]. - **TransMedics Group**: Innovates in organ transplantation with its FDA-approved Organ Care System, projecting a 30% revenue growth this year [14][15]. - **Veeva Systems**: Offers cloud-based software for life sciences, serving over 1,000 customers and positioned to capitalize on the industry's digital transformation [16].

Core Viewpoint - The Tempus AI class action lawsuit alleges that the company and its executives made misleading statements and failed to disclose critical information regarding its financial practices and operations, leading to significant stock price declines [3][4]. Group 1: Allegations Against Tempus AI - The lawsuit claims that Tempus AI inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [3]. - It is alleged that the credibility of Tempus AI's joint venture with SoftBank was compromised, creating the appearance of "round-tripping" capital to generate revenue [3]. - The business model of Ambry Genetics, acquired by Tempus AI, is said to be based on aggressive and potentially unethical billing practices, risking scrutiny and sustainability [3]. - AstraZeneca reportedly reduced its financial commitments to Tempus AI through a questionable "pass-through payment" arrangement, raising concerns about the company's financial health [3]. - These issues collectively indicate weaknesses in Tempus AI's core operations and revenue prospects [3]. Group 2: Impact of Research Report - On May 28, 2025, a research report from Spruce Point Capital Management raised multiple concerns regarding Tempus AI's management and financial reporting, resulting in a stock price drop of over 19% [4]. Group 3: Class Action Process - Investors who purchased Tempus AI common stock during the specified class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [5]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect the ability to share in any potential recovery [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6]. - The firm has been recognized for its significant recoveries in securities class action cases, including the largest recovery in history of $7.2 billion in the Enron case [6].

SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025. Tempus purports to be provide Artificial Intelligence ("AI") enabled precision medicine solutions. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegatio ...

Core Viewpoint - A class action lawsuit has been filed against Tempus AI, Inc. regarding allegations of securities fraud and unlawful business practices [2][3]. Group 1: Lawsuit Details - The lawsuit involves claims that Tempus and certain officers and directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Tempus securities during the Class Period have until August 12, 2025, to request to be appointed as Lead Plaintiff [3]. Group 2: Concerns Raised - A report by Spruce Point Capital Management on May 28, 2025, raised concerns about Tempus, including aggressive accounting and financial reporting practices [3]. - The report also highlighted that several members of Tempus's Board and executives have been associated with companies that restated financial results [3]. - Key strategic partnerships and deal announcements with AstraZeneca and Pathos AI are under scrutiny according to the report [3]. Group 3: Company Background - Pomerantz LLP, the firm handling the lawsuit, is recognized for its expertise in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for class members [4].

Core Insights - Tempus AI (TEM) is experiencing significant growth in its Data and Services segment, with a 43.2% year-over-year revenue increase to $61.9 million in Q1 2025, driven by a 58% growth in its Insights data licensing business [1][7] - The company has secured major contracts, including a $200 million licensing agreement with AstraZeneca (AZN) and Pathos, which has increased AZN's total remaining contract value to over $1 billion [2][7] - Tempus has expanded collaborations with key pharmaceutical companies, including Illumina and Boehringer Ingelheim, enhancing its position in biomarker development and oncology applications [3][7] Financial Performance - Gross profit for Tempus outpaced revenue growth, increasing by 65.2% with only a modest 3% rise in the cost of revenues [1] - Year-to-date, Tempus AI shares have surged 102.5%, significantly outperforming the industry average growth of 18% [6] Competitive Landscape - Competitors like ICON (ICLR) and IQVIA (IQV) are also experiencing growth, but Tempus AI's performance in securing contracts and expanding its service offerings positions it favorably in the market [4][5] - Tempus currently trades at a forward 12-month Price-to-Sales (P/S) ratio of 8.47X, compared to the industry average of 5.83X, indicating a premium valuation [8]

Core Viewpoint - Tempus AI, Inc. is facing a class action lawsuit due to allegations of misleading statements and undisclosed material information during the specified Class Period, which has led to significant investor losses [1][3][4]. Group 1: Class Action Details - The class action lawsuit represents investors who purchased Tempus AI securities between August 6, 2024, and May 27, 2025, with a deadline for filing a lead plaintiff motion set for August 12, 2025 [1]. - Investors are encouraged to contact the Portnoy Law Firm for a complimentary case evaluation regarding their legal rights and options for recovering losses [2]. Group 2: Allegations Against Tempus AI - The lawsuit alleges that Tempus AI inflated the value of certain contract agreements, many of which involved related parties and included non-binding opt-ins or were self-funded [3]. - Concerns were raised about a joint venture with SoftBank Group Corporation, which allegedly risked credibility by appearing to "round-trip" capital to artificially inflate revenue [3]. - The acquisition of Ambry Genetics Corporation is claimed to have operated under a business model reliant on aggressive and potentially unethical billing practices, exposing it to regulatory and financial risks [3]. - AstraZeneca PLC reportedly reduced its financial support to Tempus AI through a questionable "pass-through payment" structure involving a joint agreement with Pathos AI, Inc. [3]. - These issues are indicative of broader weaknesses in Tempus AI's core operations and long-term revenue outlook [3]. Group 3: Impact on Stock Price - Following the publication of a research report by Spruce Point Capital Management, LLC on May 28, 2025, which highlighted serious concerns regarding Tempus AI's management and operations, the company's stock price fell by over 19% [4].

Core Viewpoint - The Tempus AI class action lawsuit alleges that the company and its executives made misleading statements and failed to disclose critical information that inflated the company's stock value during the specified class period [3][4]. Group 1: Class Action Details - The class action lawsuit is titled Shouse v. Tempus AI, Inc., and it allows purchasers of Tempus AI common stock from August 6, 2024, to May 27, 2025, to seek appointment as lead plaintiff by August 12, 2025 [1]. - The lawsuit claims violations of the Securities Exchange Act of 1934 by Tempus AI and certain executives [1]. Group 2: Allegations Against Tempus AI - Allegations include that Tempus AI inflated contract values, many of which were with related parties and included non-binding opt-ins [3]. - Concerns were raised about the credibility of Tempus AI's joint venture with SoftBank, suggesting it created an appearance of "round-tripping" capital [3]. - The business model of Ambry Genetics Corporation, acquired by Tempus AI, is criticized for aggressive and potentially unethical billing practices [3]. - AstraZeneca's reduced financial commitments to Tempus AI through a questionable "pass-through payment" is also highlighted [3]. - These issues indicate weaknesses in Tempus AI's core operations and revenue prospects [3]. Group 3: Impact on Stock Price - Following a research report from Spruce Point Capital Management on May 28, 2025, which raised concerns about Tempus AI's management and financial reporting, the company's stock price fell by more than 19% [4].

Group 1 - The healthcare sector is highlighted as a significant area for the application of AI technologies, suggesting that future medical breakthroughs will likely be driven by AI advancements [1] - Tempus AI, Inc. (NASDAQ: TEM) is mentioned as a key player in the healthcare AI space, indicating its potential relevance in upcoming medical innovations [1] Group 2 - The article emphasizes the importance of core values such as excellence, integrity, transparency, and respect in achieving long-term success in the investment field [1]